论文部分内容阅读
目的 探讨ＥＭＡ－ ＣＯ 方案治疗高危、耐药妊娠滋养细胞肿瘤的疗效和可行性。方法 统计ＥＭＡ－ＣＯ方案治疗３３ 例妊娠滋养细胞肿瘤的疗效、毒副反应和化疗剂量强度的实施情况。结果 总有效率７８－７８％（２６／３３） ，高危组有效率８８－２３ ％（１５／１７） ，耐药组有效率７３－３３％ （１１／１５）；主要毒副反应为骨髓抑制和胃肠道反应，未发生致死毒副反应；按计划实施剂量强度疗程数占５２－６３％ ，影响剂量强度主要因素是骨髓抑制、病人恐惧等。结论 ＥＭＡ－ ＣＯ方案是治疗高危、耐药妊娠滋养细胞肿瘤安全、有效的方案，为保证按计划实施化疗剂量强度，可预防性使用细胞因子和抗吐。
Objective To investigate the efficacy and feasibility of EMA-CO regimen in treating high-risk, drug-resistant gestational trophoblastic tumor. Methods EMA-CO regimen in the treatment of 33 cases of gestational trophoblastic tumor efficacy, toxicity and the implementation of the dose intensity of chemotherapy. Results The total effective rate was 78-78% (26/33), that of the high risk group was 88-23% (15/17), that of the resistant group was 73-33% (11/15), and the main toxicities were myelosuppression And gastrointestinal reactions, no lethal toxicity occurred; the dose of the program to implement the number of courses accounted for 52-63%, the main factors that affect the dose intensity is bone marrow suppression, patient fear and so on. Conclusion The EMA-CO regimen is safe and effective in the treatment of high-risk, drug-resistant gestational trophoblastic tumor. To ensure the planned dose intensity of chemotherapy, cytokines and antiemetic can be used prophylactically.